SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Precision BioSciences Advances PBGENE-HBV to Phase 2

Precision BioSciences reported Phase 1 findings supporting the program’s advancement and received clearance to dose additional patients in its DMD trial.

DTIL

Related stories